Abstracts tagged "Adalimumab"

Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
Daniel J Lovell¹, Nicola Ruperto², Andreas Reiff³, Lawrence Jung⁴, Katerina Jarosova⁵, Richard Mouy⁶, Isabelle Koné-Paut⁷, Olcay Y. Jones⁸, Veronika Vargova⁹, Carine Wouters¹⁰, Ivan Lagunes Galindo¹¹, Carmen Mak¹², Hermine I. Brunner¹³ and Alberto Martini², ¹Cincinnati Children’s Medical Center and Pediatric Rheumatology Collaborative Study Group Coordinating Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Children's Hospital Los Angeles, Los Angeles, CA, ⁴Children’s National Health Systems, Washington, DC, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Hôpital Necker-Enfants Malades, Paris, France, ⁷Bicetre Hospital, APHP, University of Paris Sud, Paris, France, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹Faculty Hospital, Kosice, Slovakia, ¹⁰University Hospital Gasthuisberg, Leuven, Belgium, ¹¹AbbVie Inc., North Chicago, IL, ¹²AbbVie, North Chicago, IL, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 2382 • 2018 ACR/ARHP Annual Meeting
Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
Syuji Takei¹, Naomi Iwata², Ichiro Kobayashi^3,4, Toru Igarashi⁵, Yoko Yoshinaga⁶, Naoko Matsubara⁷, Naomi Sunaga⁸, Ayumi Ito⁷ and Shumpei Yokota⁹, ¹Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ²Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, ³Department of Allergy and Rheumatology, Chiba Children’s Hospital, Sapporo, Japan, ⁴Hokkaido University, Sapporo, Japan, ⁵Nippon Medical School, Tokyo, Japan, ⁶Evidence solution, Medical Communications, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical, AbbVie GK, Tokyo, Japan, ⁸AbbVie GK, Tokyo, Japan, ⁹Fuji Toranomon Orthopedic Hospital, Gotemba, Japan
Background/Purpose: The safety and efficacy of adalimumab (an anti-TNF-α antibody) treatment in patients with JIA have been demonstrated in clinical trials. This study was conducted…
Abstract Number: 1009 • 2018 ACR/ARHP Annual Meeting
Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis
Audrey Paoletti¹, Julien Rohmer², Juliette Pascaud³, Bineta Oumouly¹, Elodie Rivière³, Samuel Bitoun⁴, Gaetane Nocturne² and Xavier Mariette⁵, ¹U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, ⁴INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ⁵Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France
Background/Purpose: Three monocyte subsets have been described based on their CD14 and CD16 expression profiles. The subpopulation CD14+CD16+ being expanded in rheumatoid arthritis (RA) patient.…
Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Frank Weller-Heinemann⁴, Kirsten Minden⁵ and Ariane Klein⁶, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁴Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting
Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis
Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA
Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
Juliana Brunelli¹, Clovis A Silva¹, Sandra G Pasoto², Carla GS Saad², Katia T. Kozu¹, Elaine P Leon², Margarete B Vendramini², Nicole Fontoura², Eloisa Bonfa³ and Nadia E Aikawa², ¹Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…
Abstract Number: 1192 • 2018 ACR/ARHP Annual Meeting
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares
Filip van Den Bosch¹, Siegfried Wassenberg², Boulos Haraoui³, Patrick Zueger⁴, Meijing Wu⁴, Ivan Lagunes Galindo⁴ and Andrew Ostor⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumazentrum Ratingen, Ratingen, Germany, ³Université de Montréal, Montreal, QC, Canada, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Melbourne, Australia
Background/Purpose: The AbbVie patient (pt) support program (PSP) is offered to pts prescribed adalimumab for RA and other indications. The purpose of this analysis was…
Abstract Number: 2395 • 2018 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals
Daniel Groth¹, Maria Perez², Simona Nativ³, James R. Treat⁴, Leslie Castelo-Soccio⁴, Pamela F. Weiss⁵, Marissa J. Perman⁴ and Sivia Lapidus³, ¹Pediatrics, Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ⁴Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The development of psoriasis while on TNFi is a paradoxical effect of agents that treat psoriasis and is described in larger cohorts inflammatory bowel…
Abstract Number: 1529 • 2018 ACR/ARHP Annual Meeting
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
Leslie R. Harrold^1,2, Jenny Griffith³, Heather J Litman⁴, Bernice Gershenson¹, Syed Islam³, Christine J Barr², Dianlin Guo³, Patrick Zueger⁵, Jonathan Fay³ and Jeffrey Greenberg^2,6, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴Corrona LLC, Waltham, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶New York University School of Medicine, New York, NY
Background/Purpose: The incidence of adverse events (AE) among rheumatology medication users has not been well documented in real-world disease registry datasets in the US. We…
Abstract Number: 2397 • 2018 ACR/ARHP Annual Meeting
The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Kirsten Minden³, Pierre Quartier⁴, Jaclyn K. Anderson⁵, Kristina Unnebrink⁶, Ivan Lagunes Galindo⁵ and Gerd Horneff⁷, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Charite University Medicine, Berlin, Germany, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co., Ludwigshafen, Germany, ⁷Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany
Background/Purpose: Children with one or more subtypes of juvenile idiopathic arthritis, such as enthesitis-related arthritis (ERA), often exhibit growth impairments. The purpose of the analysis…
Abstract Number: 1532 • 2018 ACR/ARHP Annual Meeting
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Paul Emery¹, Michael E Weinblatt², Josef S. Smolen³, Edward C. Keystone⁴, Mark C. Genovese⁵, Jiri Vencovsky⁶, Jonathan Kay⁷, Evelyn Hong⁸ and Jeehoon Ghil⁸, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Stanford University Medical Center, Palo Alto, CA, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ⁷UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. The phase III randomized, double-blind clinical studies comparing the efficacy and…
Abstract Number: 2522 • 2018 ACR/ARHP Annual Meeting
Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
Stanley Cohen¹, Niklas Czeloth², Eric Lee³, Piotr A. Klimiuk⁴, Nuala Peter⁵ and Girish Jayadeva², ¹Metroplex Clinical Research Center, Dallas, TX, ²Boehringer Ingelheim, Ingelheim a.R., Germany, Ingelheim, Germany, ³Inland Rheumatology, Upland, CA, ⁴Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, ⁵Boehringer Ingelheim, Biberach a.d.R., Germany, Ingelheim a.R., Germany
Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…
Abstract Number: 1420 • 2017 ACR/ARHP Annual Meeting
The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab
Josef S. Smolen¹, Prashanth Sunkureddi², Jaclyn K. Anderson³, Jenny Griffith³, Dingfeng Jiang³, Kun Chen³, Jessica L. Suboticki⁴ and Arthur Kavanaugh⁵, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Clear Lake Rheumatology, Nassau Bay, TX, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with…
Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Dimitrios A. Pappas¹, Chitra Karki¹, Ying Shan¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.